Typhoid Fever Vaccines Market Size, Trends and Growth Analysis by 2027

The market for Typhoid fever vaccines was valued at approximately US$ 262.81 million in 2019 and is anticipated to grow to around US$ 525.32 million by 2027, reflecting a compound annual growth rate (CAGR) of 9.3% from 2020 to 2027.

The expansion of the Typhoid fever vaccines market can be primarily attributed to the increasing incidence of typhoid fever and the efforts of various organizations advocating for typhoid immunization. Nevertheless, the market may face challenges due to potential side effects associated with these vaccines during the forecast period.

Typhoid fever is particularly prevalent in rural and underdeveloped regions. According to recent data from the World Health Organization (WHO), typhoid is endemic in several areas, including Africa, Asia, Latin America, Oceania, and the Caribbean. The WHO reports that approximately 80% of typhoid cases occur in countries such as India, Bangladesh, China, Laos, Nepal, Indonesia, Vietnam, and Pakistan. A study conducted by the All India Institute of Medical Sciences (AIIMS) revealed that in 2017, around 494 out of every 100,000 children aged 5 to 15 years were affected by typhoid.

Numerous manufacturers and non-governmental organizations worldwide are dedicated to raising awareness and promoting research aimed at developing new, effective, and innovative vaccines to fight typhoid. This commitment has resulted in the approval of several vaccine candidates by regulatory authorities in recent years, which is expected to further stimulate the growth of the typhoid fever vaccine market. Additionally, various governments have implemented strategies and policies to support vaccination and immunization initiatives against typhoid fever within their jurisdictions.

The Typhoid fever vaccines market is categorized based on vaccine type into live attenuated vaccines, capsular polysaccharide vaccines, conjugate vaccines, and others. In 2019, the capsular polysaccharide vaccines segment held the largest market share. The growth of this segment is driven by its effectiveness in preventing infections and the increasing number of patients globally. It is also projected to experience the highest CAGR in the global Typhoid fever vaccines market throughout the forecast period.

In terms of administration routes, the market is divided into oral and injectable vaccines. The injectable segment dominated the market in 2019, while the oral segment is expected to witness the highest CAGR during the forecast period.

The COVID-19 pandemic has posed significant challenges worldwide, particularly in developing nations. The pandemic has disrupted global trade, leading to reduced imports and shortages of medical supplies, which in turn has caused substantial price increases. The WHO and UNICEF have raised alarms about a concerning decline in the number of children receiving essential vaccines globally, attributed to interruptions in immunization services caused by the pandemic. In 2019, UNICEF procured approximately 2.43 billion doses of vaccines for around 100 countries, reaching about 45% of children under five years old worldwide.

Key organizations such as the World Health Organization (WHO), the Food and Drug Administration (FDA), UNICEF, the All India Institute of Medical Sciences, National Health Services, and the Centers for Disease Control and Prevention have been instrumental in providing data and insights for this report.